Tag Archives: NWBO

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) just filed its 2016 10-K with the SEC, and as we might have predicted, our competitors over at the street (and in particular, one Adam Feuerstein) has followed the submission with a hit piece. We...

Northwest Biotherapeutics Inc (OTCMKTS:NWBO) just announced a registered direct offering, and the company is down more than 50% on the news. This isn’t the first time we have seen something like this from Northwest, and chances are it won’t...

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) has been a real tough stock to hold over the last couple of years. It’s fallen prey to aggressive short sell type manipulation. It’s had clinical halt related development setbacks for...

For a long time, we’ve kept Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) on our radar. The company has been one of the hardest stocks to read over the last eighteen months, rooted in a clinical hold on its lead asset, and sentiment surrounding...

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) is drawing a considerable amount of what can only be referred to as ridicule right now. The company put out a press release early December addressing the progress of its long-standing glioblastoma...

Ask a group of small cap biotechnology investors to name one of the most frustrating companies in the space over the last 12 months, and chances are you’ll hear the name Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) more than once. The...

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shareholders have been waiting for some level of insight into its brain cancer trial for more than twelve months. Since enrollment came to a halt last year, the company has refused (or been unable,...

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) just announced that it is voluntarily delisting its stock from NASDAQ in favor of an over the counter listing, and markets have responded positively to the news. The general view of a delisting is...

Well, here’s one for the books. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) just put out a fresh press release, updating markets as to the progress of its operations. Well, sort of. We didn’t get too much information on the current...

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is grabbing headlines again. The company put out some data at the end of September purporting to a phase 1 trial of its DCVax-Direct treatment, and response has been mixed. At first glance, the data...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter